cefuroxime axetil Tablet BP 250 mg

Cefuroxime axetil is indicated for the treatment of the infections listed below in adults and children from the age of 3 months.
– Acute streptococcal tonsillitis and pharyngitis.
– Acute bacterial sinusitis.
– Acute otitis media.
– Acute exacerbations of chronic bronchitis.
– Cystitis
– Pyelonephritis.
– Uncomplicated skin and soft tissue infections.
– Treatment of early Lyme disease.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The usual course of therapy is seven days (may range from five to ten days).

The most common adverse reactions are Candida overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes. Candida overgrowth, eosinophilia, headache, dizziness, diarrhoea, nausea, abdominal pain, transient increases of hepatic enzyme levels

Hypersensitivity reactions
Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.
Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Jarisch-Herxheimer reaction
The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

Overgrowth of non-susceptible microorganisms
As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment.
Antibacterial agent–associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime. Discontinuation of therapy with cefuroxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.

Store below 30°C and protect from light and moisture.
Keep the medicine out of reach of children.

10 × 10 Alu/Alu Blister.
CVPROX-500 tablets are available in an Alu/Alu blister of 10 tablets. Such 10 blisters in a unit carton with pack insert.